The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fosciclopirox clinical proof of concept in patients with nonmuscle invasive and muscle-invasive bladder cancer.
 
Scott James Weir
Research Funding - CicloMed (Inst)
Patents, Royalties, Other Intellectual Property - Co-Inventor on issued Ciclopirox Prodrug composition-of-matter and methods-of-use patents
(OPTIONAL) Uncompensated Relationships - CicloMed
 
Elizabeth R Kessler
Stock and Other Ownership Interests - Johnson and Johnson
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Medivation/Astellas; Merck Serono (Inst); Pfizer (Inst)
 
Janet Baack Kukreja
Consulting or Advisory Role - Arquer Diagnostics; AstraZeneca; Photocure
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Inspirna (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Manojkumar Bupathi
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Pfizer
 
Rahul Atul Parikh
Stock and Other Ownership Interests - Myovant Sciences (I)
Consulting or Advisory Role - Merck
Research Funding - Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Elizabeth Marie Wulff-Burchfield
Stock and Other Ownership Interests - Immunomedics (I); Nektar (I)
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AVEO; Bristol-Myers Squibb; Exelixis; Janssen Oncology
Research Funding - Pfizer
 
Robyn Wood
No Relationships to Disclose
 
Eugene K. Lee
No Relationships to Disclose
 
Tammy Ham
Employment - CicloMed
Leadership - CicloMed
 
Prasad Dandawate
No Relationships to Disclose
 
Shrikant Anant
No Relationships to Disclose
 
Benjamin L. Woolbright
No Relationships to Disclose
 
Na Zhang
No Relationships to Disclose
 
Paul Toren
No Relationships to Disclose
 
Michael Dalton
No Relationships to Disclose
 
Valentina Zhukova-Harrill
No Relationships to Disclose
 
Jay Nicholas Umbreit
No Relationships to Disclose
 
William McCulloch
Employment - 3-V Biosciences; CicloMed; Ribon Therapeutics; Sagimet Biosciences
Leadership - 3-V Biosciences; Sagimet Biosciences
Stock and Other Ownership Interests - 3-V Biosciences; Sagimet Biosciences
Consulting or Advisory Role - CicloMed; Idera; Ribon Therapeutics
Patents, Royalties, Other Intellectual Property - Issued patents relating to romidepsin (Istodax(R)) assigned to Celgene, Inc. No financial interest.
Travel, Accommodations, Expenses - CicloMed; Ribon Therapeutics
 
John A. Taylor
Honoraria - ASCO
Consulting or Advisory Role - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - PCT/US11/21721. Use of Isoxazoline compounds and compositions in bladder cancer. Inventors: Taylor JA and Sielecki TM
Other Relationship - Photocure